RxDoctor Payments Data

Robert Price, MD

Ophthalmology · Knoxville, TNNPI 1922093988

Payments from drug & device makers

$3,053in general payments, 2019–2025

Across 145 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$275
  • Sight Sciences, Inc.$238
  • Tarsus Pharmaceuticals, Inc.$227
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$151
  • Rxsight Inc$137
  • plus $695 from 12 others

What the payments were for

  • Food & beverage$2,98998%
  • Gifts$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,053 in reported general payments places this provider in the 60th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$246,931
Medicare patients
763
Services billed
2,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost235$163,627
LumiganBimatoprost182$93,883
CombiganBrimonidine Tartrate/Timolol125$51,483
VyzultaLatanoprostene Bunod80$40,457
RestasisCyclosporine27$30,293
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol66$14,748
Travoprost62$12,980
Cyclosporine12$11,898
MieboPerfluorohexyloctane/Pf15$11,351
Alphagan PBrimonidine Tartrate18$9,330
SimbrinzaBrinzolamide/Brimonidine Tart23$7,335
Latanoprost589$6,783
Brimonidine Tartrate127$6,165
Prednisolone Acetate106$6,021
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat289$5,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$1,331$184,988352 claims
Aerie Pharmaceuticals, Inc.Rocklatan$124$163,627235 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$117$51,80995 claims
AlconSimbrinza$275$7,33523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →